Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gold Nanoparticles Show Potential for "Cooking” Cancer Cells

By LabMedica International staff writers
Posted on 09 Apr 2009
Researchers are reporting a long-awaited development toward applying the wonders of nanotechnology in the fight against cancer. More...
They have developed the first hollow gold nanospheres --smaller than the tiniest flecks of dust--that seek out and "cook" cancer cells. The cancer-destroying nanospheres demonstrate particular promise as a minimally invasive future treatment for malignant melanoma, the deadliest form of skin cancer.

Melanoma now causes more than 8,000 deaths annually in the United States alone and is increasing globally. The researchers presented their findings at the American Chemical Society's 237th U.S. national meeting, held in Salt Lake City, UT, USA, in March 2009. The gold nanospheres are equipped with a special peptide; that protein fragment draws the nanospheres directly to melanoma cells, while avoiding healthy skin cells. After collecting inside the cancer, the nanospheres heat up when exposed to near-infrared light, which penetrates deeply through the surface of the skin. In recent research in mice, the hollow gold nanospheres did eight times more damage to skin tumors than the same nanospheres without the targeting peptides, according to the researchers.

"This technique is very promising and exciting," explained study coauthor Jin Zhang, Ph.D., a professor of chemistry and biochemistry at the University of California in Santa Cruz (USA). "It's basically like putting a cancer cell in hot water and boiling it to death. The more heat the metal nanospheres generate, the better." This form of cancer therapy is actually a variation of photothermal ablation, also known as photoablation therapy (PAT), a technique in which doctors use light to burn tumors. Since the technique can destroy healthy skin cells, clinicians must carefully control the duration and intensity of treatment.

Researchers now know that PATs can be greatly enhanced by applying a light-absorbing material, such as metal nanoparticles, to the tumor. Although researchers have developed various types of metal nanoparticles to help improve this technique, many materials show poor penetration into cancer cells and limited heat carrying capacities. These particles include solid gold nanoparticles and nanorods that lack the desired combination of spherical shape and strong near-infrared light absorption for effective PAT, according to the scientists.

To develop more effective cancer-burning compounds, Dr. Zhang and colleagues focused on hollow gold nanospheres--each approximately 1/50,000th the width of a single human hair. Previous studies by others suggest that gold "nanoshells" have the potential for strong near-infrared light absorption. However, scientists have been largely not capable of producing them effectively in the lab, Dr. Zhang noted.

After years of research toward this goal, Dr. Zhang announced in 2006 that he had finally developed a nanoshell or hollow nanosphere with the appropriate agent for cancer therapy: Gold spheres with an optimal light absorption capacity in the near-infrared region, small size, and spherical shape, ideal for penetrating cancer cells and burning them up. "Previously developed nanostructures such as nanorods were like chopsticks on the nanoscale," Dr. Zhang said. "They can go through the cell membrane, but only at certain angles. Our spheres allow a smoother, more efficient flow through the membranes."

The gold nanoshells, which are nearly perfect spheres, range in size from 30-50 nanometers--thousands of times smaller than the width of a human hair. The shells are also much smaller than other nanoparticles previously designed for photoablation therapy, according to Dr. Zhang. Another advantage is that gold is also safer and has fewer side effects in the body than other metal nanoparticles, he noted.

Working with Chun Li, Ph.D., a professor at the University of Texas M.D. Anderson Cancer Center (Houston, TX, USA), Dr. Zhang and his associates equipped the nanospheres with a peptide to a protein receptor that is abundant in melanoma cells, giving the nanospheres the ability to target and destroy skin cancer. In experiments using mice, the resulting nanospheres were found to be considerably more effective than solid gold nanoparticles due to much stronger near infrared-light absorption of the hollow nanospheres, the researchers say.

The next step is to try the nanospheres in humans, according to Dr. Zhang. This requires extensive preclinical toxicity studies. The mice study is the first step, and there is a long way to go before it can be put into clinical practice.

Related Links:

University of California, Santa Cruz




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.